BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

633 related articles for article (PubMed ID: 16984246)

  • 21. Iodine biokinetics and radioiodine exposure after recombinant human thyrotropin-assisted remnant ablation in comparison with thyroid hormone withdrawal.
    Taïeb D; Sebag F; Farman-Ara B; Portal T; Baumstarck-Barrau K; Fortanier C; Bourrelly M; Mancini J; De Micco C; Auquier P; Conte-Devolx B; Henry JF; Mundler O
    J Clin Endocrinol Metab; 2010 Jul; 95(7):3283-90. PubMed ID: 20392868
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Value of diagnostic radioiodine scintigraphy and thyroglobulin measurements after rhTSH injection.
    Verburg FA; de Keizer B; de Klerk JM; Lentjes EG; Lips CJ; van Isselt JW
    Nuklearmedizin; 2009; 48(1):26-9. PubMed ID: 19212608
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recombinant human TSH in radioiodine treatment of differentiated thyroid cancer.
    Kovatcheva RD; Hadjieva TD; Kirilov GG; Lozanov BS
    Nucl Med Rev Cent East Eur; 2004; 7(1):13-9. PubMed ID: 15318305
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recombinant thyroid-stimulating hormone in differentiated thyroid cancer.
    Krausz Y; Uziely B; Nesher R; Chisin R; Glaser B
    Isr Med Assoc J; 2001 Nov; 3(11):843-9. PubMed ID: 11729583
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recombinant human TSH (rhTSH) in 2009: new perspectives in diagnosis and therapy.
    Molinaro E; Viola D; Passannanti P; Agate L; Lippi F; Ceccarelli C; Pinchera A; Elisei R
    Q J Nucl Med Mol Imaging; 2009 Oct; 53(5):490-502. PubMed ID: 19910902
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical experience with recombinant human thyroid-stimulating hormone (rhTSH): whole-body scanning with iodine-131.
    Reiners C; Luster M; Lassmann M
    J Endocrinol Invest; 1999; 22(11 Suppl):17-24. PubMed ID: 10727001
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma.
    Lee J; Yun MJ; Nam KH; Chung WY; Soh EY; Park CS
    Thyroid; 2010 Feb; 20(2):173-9. PubMed ID: 20151824
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Uses for recombinant human TSH in patients with thyroid cancer and nodular goiter.
    Woodmansee WW; Haugen BR
    Clin Endocrinol (Oxf); 2004 Aug; 61(2):163-73. PubMed ID: 15272910
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Incidence and implications of negative serum thyroglobulin but positive I-131 whole-body scans in patients with well-differentiated thyroid cancer prepared with rhTSH or thyroid hormone withdrawal.
    Cherk MH; Francis P; Topliss DJ; Bailey M; Kalff V
    Clin Endocrinol (Oxf); 2012 May; 76(5):734-40. PubMed ID: 22050475
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnostic and therapeutic use of recombinant human TSH (rhTSH) in differentiated thyroid cancer.
    Pacini F; Castagna MG
    Best Pract Res Clin Endocrinol Metab; 2008 Dec; 22(6):1009-21. PubMed ID: 19041828
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up.
    Molinaro E; Giani C; Agate L; Biagini A; Pieruzzi L; Bianchi F; Brozzi F; Ceccarelli C; Viola D; Piaggi P; Vitti P; Pacini F; Elisei R
    J Clin Endocrinol Metab; 2013 Jul; 98(7):2693-700. PubMed ID: 23626005
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal.
    Elisei R; Schlumberger M; Driedger A; Reiners C; Kloos RT; Sherman SI; Haugen B; Corone C; Molinaro E; Grasso L; Leboulleux S; Rachinsky I; Luster M; Lassmann M; Busaidy NL; Wahl RL; Pacini F; Cho SY; Magner J; Pinchera A; Ladenson PW
    J Clin Endocrinol Metab; 2009 Nov; 94(11):4171-9. PubMed ID: 19850694
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical experience with recombinant human thyrotrophin (rhTSH) in the management of patients with differentiated thyroid cancer.
    Mariani G; Ferdeghini M; Augeri C; Villa G; Taddei GZ; Scopinaro G; Boni G; Bodei L; Rabitti C; Molinari E; Bianchi R
    Cancer Biother Radiopharm; 2000 Apr; 15(2):211-7. PubMed ID: 10803328
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Use of recombinant human TSH for stimulation of iodine radioisotope uptake in metastases of thyroid cancer during therapy with 131I].
    Roskosz J; Handkiewicz-Junak D; Turska M; Wygoda Z; Jurecka-Tuleja B; Jarzab B
    Wiad Lek; 2001; 54 Suppl 1():289-96. PubMed ID: 12182037
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recombinant human thyroid-stimulating hormone (Thyrogen) in thyroid cancer follow up: experience at a single institution.
    Wong R; Topliss DJ; Bach LA; Hamblin PS; Kalff V; Long F; Stockigt JR
    Intern Med J; 2009 Mar; 39(3):156-63. PubMed ID: 19383064
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of recombinant human thyrotropin before radioiodine therapy in patients with advanced differentiated thyroid carcinoma.
    Luster M; Lassmann M; Haenscheid H; Michalowski U; Incerti C; Reiners C
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3640-5. PubMed ID: 11061516
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Radioiodine treatment of metastatic differentiated thyroid cancer in patients on L-thyroxine, using recombinant human TSH.
    Lippi F; Capezzone M; Angelini F; Taddei D; Molinaro E; Pinchera A; Pacini F
    Eur J Endocrinol; 2001 Jan; 144(1):5-11. PubMed ID: 11174831
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A pragmatic protocol for I-131 rhTSH-stimulated ablation therapy in patients with renal failure.
    Driedger AA; Quirk S; McDonald TJ; Ledger S; Gray D; Wall W; Yoo J
    Clin Nucl Med; 2006 Aug; 31(8):454-7. PubMed ID: 16855429
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High prevalence of side effects after recombinant human thyrotropin-stimulated radioiodine treatment with 30 mCi in patients with multinodular goiter and subclinical/clinical hyperthyroidism.
    Romão R; Rubio IG; Tomimori EK; Camargo RY; Knobel M; Medeiros-Neto G
    Thyroid; 2009 Sep; 19(9):945-51. PubMed ID: 19678745
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Real time RT-PCR analysis of thyroglobulin mRNA in peripheral blood in patients with congenital athyreosis and with differentiated thyroid carcinoma after stimulation with recombinant human thyrotropin.
    Kaufmann S; Schmutzler C; Schomburg L; Körber C; Luster M; Rendl J; Reiners C; Köhrle J
    Endocr Regul; 2004 Jun; 38(2):41-9. PubMed ID: 15497927
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.